Oxford University spinout Dark Blue Therapeutics acquired to advance leukaemia treatment
The acquisition is expected to help accelerate the development of a new type of targeted treatment for leukaemia, with the potential to improve outcomes for patients. It is also hoped that this treatment could be expanded to other cancers.The scientific foundations of the programmes were built on discoveries made by Oxford researchers including Oleg Fedorov, Cassandra Adams, Gilian Farnie, Kilian Huber and Paul Brennan in the Centre for Medicines Discovery;…

